TheraRadar
← Back
Data updated: Jun 28, 2026

A-OX WELDING SUPPLY CO, INC.

Pharma
Pharmaceuticals

A-OX WELDING SUPPLY CO, INC. is a pharmaceutical company with 2 FDA-approved products.

2018
Since
2
Drugs
-
Trials
6
New Drugs (2yr)
Modality:
2 Small Molecules

A-OX WELDING SUPPLY CO, INC.'s Key Drugs

A-OX WELDING SUPPLY CO, INC.'s core commercial portfolio centers on HELIUM, USP, CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.

HELIUM, USP
Respiratory
Approved 2013
CARBON DIOXIDE, USP
Respiratory
Approved 2013

A-OX WELDING SUPPLY CO, INC.'s Recent FDA Approvals

A-OX WELDING SUPPLY CO, INC. secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

CARBON DIOXIDE, USP NDA
2025-10-25
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-06-16
carbon dioxide
CARBON DIOXIDE, USP NDA
2025-04-21
carbon dioxide
Carbon Dioxide, USP NDA
2025-02-02
carbon dioxide
Carbon Dioxide, USP NDA
2024-11-09
carbon dioxide, usp
CARBON DIOXIDE, USP NDA
2024-08-10
carbon dioxide

A-OX WELDING SUPPLY CO, INC.'s Therapeutic Areas

Disease areas where A-OX WELDING SUPPLY CO, INC. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

A-OX WELDING SUPPLY CO, INC. Pipeline Snapshot

Active clinical trials for A-OX WELDING SUPPLY CO, INC. across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • HELIUM, USP leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling